Danaher Corporation $DHR Shares Sold by Foster Victor Wealth Advisors LLC

Key Points

• Foster Victor Wealth Advisors LLC reduced its Danaher stake by 12.8%, selling 11,742 shares and ending the quarter with 79,914 shares worth about $18.86 million (roughly 1.1% of the firm's holdings, its 23rd largest position).
• EVP Gregory M. Milosevich sold 1,320 shares at an average price of $208.01 for $274,573, a 20.56% cut to his holding; company insiders now own about 10.8% of Danaher.
• Danaher beat quarterly expectations (EPS $2.23 vs. $2.14; revenue $6.84B vs. $6.79B) and raised its quarterly dividend to $0.40 (annualized $1.60, yield ~0.8%, ex‑dividend March 27).

Foster Victor Wealth Advisors LLC lessened its stake in Danaher Corporation (NYSE:DHR - Free Report) by 12.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 79,914 shares of the conglomerate's stock after selling 11,742 shares during the quarter. Danaher makes up approximately 1.1% of Foster Victor Wealth Advisors LLC's holdings, making the stock its 23rd biggest holding. Foster Victor Wealth Advisors LLC's holdings in Danaher were worth $18,859,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. JPL Wealth Management LLC acquired a new stake in Danaher during the third quarter worth about $25,000. WFA of San Diego LLC acquired a new stake in Danaher during the second quarter worth about $26,000. ANTIPODES PARTNERS Ltd acquired a new stake in Danaher during the third quarter worth about $27,000. TruNorth Capital Management LLC acquired a new stake in Danaher during the third quarter worth about $28,000. Finally, Tripletail Wealth Management LLC acquired a new stake in Danaher during the third quarter worth about $31,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president owned 5,099 shares of the company's stock, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 10.80% of the company's stock.

Danaher Stock Performance

DHR opened at $198.58 on Wednesday. The business's 50 day moving average is $200.12 and its 200-day moving average is $214.88. The stock has a market cap of $140.54 billion, a PE ratio of 39.40, a price-to-earnings-growth ratio of 2.66 and a beta of 0.95. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35. Danaher Corporation has a twelve month low of $180.03 and a twelve month high of $242.80.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, January 27th. The conglomerate reported $2.23 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.09. The company had revenue of $6.84 billion for the quarter, compared to analysts' expectations of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.14 earnings per share. On average, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. This is a boost from Danaher's previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Friday, March 27th. Danaher's dividend payout ratio is presently 31.75%.

Analyst Ratings Changes

Several research firms recently weighed in on DHR. KeyCorp reiterated an "overweight" rating on shares of Danaher in a research note on Thursday, January 29th. Guggenheim increased their price objective on shares of Danaher from $250.00 to $275.00 and gave the stock a "buy" rating in a research note on Friday, January 2nd. Robert W. Baird set a $251.00 price objective on shares of Danaher in a research note on Thursday, January 29th. TD Cowen dropped their price objective on shares of Danaher from $270.00 to $245.00 and set a "buy" rating on the stock in a research note on Monday. Finally, Argus set a $265.00 price objective on shares of Danaher in a research note on Wednesday, January 14th. Eighteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $247.35.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Beckman Coulter Diagnostics (a Danaher unit) received CE mark for the Access MeMed BV assay, a high-throughput host‑response test that differentiates bacterial vs. viral infections in ~20 minutes — a commercial approval that could support diagnostics revenue and adoption in Europe. Beckman Coulter Diagnostics Earns CE Mark
• Positive Sentiment: Sector tailwind: cell therapy and regenerative medicine markets are forecast to grow strongly (high single- to double-digit CAGR), supporting long-term demand for life-science tools and services that benefit parts of Danaher’s portfolio. Cell Therapy Market Growth
• Neutral Sentiment: Danaher confirmed an upcoming earnings release next Tuesday — investors will focus on revenue growth, margin commentary and guidance for reaction. Danaher to Release Earnings
• Neutral Sentiment: Market commentary pieces are tracking recent share moves and volume, but contain no new material company guidance — useful for sentiment context but not new fundamentals. Share Price Commentary
• Negative Sentiment: Analysts trimmed price targets this week: TD Cowen cut its target to $245 (from $270) but kept a Buy rating, and Goldman lowered its target to $230 (from $265) while also retaining Buy — lower targets reduce implied upside even if convictions remain. TD Cowen Adjusts Price Target Goldman Target Cut
• Negative Sentiment: Pre-earnings analyst commentary (Zacks/Yahoo) suggests Danaher lacks the setup that typically yields an earnings beat in the coming report — if results or guidance disappoint, the stock could underperform near term. Earnings Beat Odds

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.